Association of Low-Grade Albuminuria With Adverse Cardiac Mechanics
Association of Low-Grade Albuminuria With Adverse Cardiac Mechanics
Association of Low-Grade Albuminuria With Adverse Cardiac Mechanics
Cardiac Mechanics
Findings From the Hypertension Genetic Epidemiology Network
(HyperGEN) Study
Daniel H. Katz, BA; Senthil Selvaraj, MD, MA; Frank G. Aguilar, MPH; Eva E. Martinez, BA;
Lauren Beussink, MHS, RDCS; Kwang-Youn A. Kim, PhD; Jie Peng, MS; Jin Sha, MS;
Marguerite R. Irvin, PhD; John H. Eckfeldt, MD, PhD; Stephen T. Turner, MD;
Barry I. Freedman, MD; Donna K. Arnett, PhD, MSPH; Sanjiv J. Shah, MD
BackgroundAlbuminuria is a marker of endothelial dysfunction and has been associated with adverse cardiovascular
outcomes. The reasons for this association are unclear but may be attributable to the relationship between endothelial
dysfunction and intrinsic myocardial dysfunction.
Methods and ResultsIn the Hypertension Genetic Epidemiology Network (HyperGEN) Study, a population- and familybased study of hypertension, we examined the relationship between urine albumin-to-creatinine ratio (UACR) and cardiac
mechanics (n=1894, all of whom had normal left ventricular ejection fraction and wall motion). We performed speckletracking echocardiographic analysis to quantify global longitudinal, circumferential, and radial strain, and early diastolic
(e) tissue velocities. We used E/e ratio as a marker of increased left ventricular filling pressures. We used multivariableadjusted linear mixed effect models to determine independent associations between UACR and cardiac mechanics.
The mean age was 5014 years, 59% were female, and 46% were black. Comorbidities were increasingly prevalent
among higher UACR quartiles. Albuminuria was associated with global longitudinal strain, global circumferential
strain, global radial strain, e velocity, and E/e ratio on unadjusted analyses. After adjustment for covariates, UACR was
independently associated with lower absolute global longitudinal strain (multivariable-adjusted mean global longitudinal
strain [95% confidence interval] for UACR Quartile 1 = 15.3 [15.015.5]% versus UACR Q4 = 14.6 [14.314.9]%, P for
trend<0.001) and increased E/e ratio (Q1 = 25.3 [23.527.1] versus Q4 = 29.0 [27.031.0], P=0.003). The association
between UACR and global longitudinal strain was present even in participants with UACR < 30 mg/g (P<0.001 after
multivariable adjustment).
ConclusionsAlbuminuria, even at low levels, is associated with adverse cardiac mechanics and higher E/e
ratio.(Circulation. 2014;129:42-50.)
Key Words:albuminuria echocardiography ventricular function
Clinical Perspective on p 50
Assessment of subclinical myocardial dysfunction has
advanced considerably with the advent of tissue Doppler
imaging and speckle-tracking echocardiography, which allow
for the measurement of tissue velocities and myocardial strain,
DOI: 10.1161/CIRCULATIONAHA.113.003429
Methods
Study Population
HyperGEN, part of the National Institutes of Health Family Blood
Pressure Program, is a cross-sectional study consisting of 5 U.S.
sites, with 4 participating in an ancillary echocardiographic study
(Salt Lake City, Utah; Forsyth County, North Carolina; Minneapolis,
Minnesota; and Birmingham, Alabama). The goal of HyperGEN
was to identify and characterize the genetic basis of familial hypertension; complete details of the HyperGEN study design have
been reported previously.13 Study eligibility required a diagnosis
of hypertension before the age of 60 years and 1 affected sibling
willing to participate in the study. Normotensive, age-matched controls were drawn from the same base populations as the hypertensive participants. Hypertension was defined by an average systolic
blood pressure 140 mmHg or an average diastolic blood pressure
90 mmHg (on at least 2 separate clinic visits) or by self-reported
treatment for hypertension. Individuals with a history of type 1
diabetes mellitus (DM) or end-stage renal disease were excluded
because of the high risk of secondary forms of hypertension. None
of the HyperGEN participants had symptomatic HF. For the present study, participants with left ventricular (LV) ejection fraction
(LVEF) <50% or abnormal wall motion score were excluded. All
HyperGEN study participants gave written informed consent, and
the HyperGEN study was approved by each study sites local institutional review board.
Statistical Analysis
Study participants were divided into UACR quartiles for descriptive purposes. Because the range of UACR values differed by sex,
we used sex-specific UACR quartiles, an approach used previously.2
To do so, quartile cutoffs were determined independently for men
and women, and then combined to give each quartile an equal gender
composition. For all regression models, UACR (predictor variable)
was log-transformed to normalize its distribution (raw UACR was
right-skewed) and to increase the linearity of the association between
UACR and speckle-tracking parameters (outcome variables).
We described clinical characteristics, laboratory data, and conventional echocardiographic parameters by UACR quartile. Continuous
data were presented as meanstandard deviation. Categorical variables were presented as a count and percentage. To test for trends
in clinical characteristics, laboratory data, and conventional echocardiographic parameters across quartiles, we examined the association between each parameter and UACR using linear mixed effects
models, adjusted only for the random effect of relatedness among
HyperGEN participants. In these models, we treated UACR as a continuous (log-transformed) variable. Cardiac mechanics and filling
pressures were similarly described by UACR quartile and analyzed
using UACR as a continuous variable.
We used multivariable-adjusted linear mixed effects models (to
account for relatedness among HyperGEN participants) to determine whether UACR was independently associated with worse
cardiac mechanics and elevated E/e ratio. Subgroup analyses were
performed in participants (1) without LVH, (2) without DM, and (3)
44CirculationJanuary 7, 2014
without hypertension. We also analyzed the subgroup of participants
who did not have clinical micro- or macroalbuminuria (ie, UACR
<30 mg/g). For descriptive purposes, we reported the estimated mean
value of each index of cardiac mechanics (or filling pressure) by quartile using the multivariable model. The estimated means in Quartiles
2, 3, and 4 were also compared with Quartile 1 to assess for significant differences.
For the multivariable analyses, covariates included speckletracking technician, image quality, study site (which accounts for
differences in sonographers and echocardiography machines), and
additional covariates that were selected using a combination of clinical relevance and association with albuminuria in previous studies.
These additional covariates included age, sex, body mass index, diagnosis of DM, history of CAD, systolic blood pressure, use of antihypertensive medication, history of smoking, GFR, LV mass index,
and LVEF. We also created and tested additional mixed effects linear
models that adjusted for the following: (1) race/ethnicity instead of
study site (race/ethnicity and study site were highly collinear because
2 sites recruited only white participants and 1 site only recruited
black participants); and (2) angiotensin converting enzyme-inhibitor/
angiotensin receptor blocker or nondihydropiridine calcium channel
blocker use instead of any antihypertensive medication use, as these
drugs are known to specifically reduce albuminuria beyond their
blood pressure-lowering effects.22 For GLS, we further adjusted for
arterial stiffness (pulse pressure/stroke volume ratio) and diastolic
function (e velocity). To present -coefficients and 95% confidence
intervals (CIs) in a clinically relevant manner, -coefficients and
95% CIs for natural log transformed UACR are multiplied by ln(2).
This translates to the change in the outcome variable for each 100%
increase (or doubling) in UACR.
We evaluated intra- and interobserver reliability in a randomly
selected sample of 95 unrelated study participants. These echocardiograms were analyzed by 2 independent readers, blinded to
each others measurements and all other data. Intraobserver measurements were performed by a single reader 1 month after initial
measurement. We evaluated the reproducibility of speckle-tracking
measurements by calculating intraclass correlation coefficient and
mean bias (Table I in the online-only Data Supplement). Statistical
analyses were performed using Stata 12.1 software (StataCorp,
College Station, TX).
Results
Characteristics of the Study Participants
From an initial sample size of 2129 HyperGEN participants,
235 were excluded because of LVEF <50% or presence of a
wall motion abnormality, leaving a sample size of n=1894
for the present study. Median UACR was 4.1 (25th75th percentile 2.48.8) mg/g in women and 3.3 (25th75th percentile
2.17.3) mg/g in men. Microalbuminuria (UACR 30300
mg/g) was present in 140 (7%) participants, and macroalbuminuria (UACR >300 mg/g) was present in 50 (3%) participants. Table1 shows baseline clinical and echocardiographic
characteristics by quartile. The cohort had a mean age of
50 years. Females were more prevalent than males, making
up 59% of the cohort. Nearly half of the participants were
black, and they were more likely to have elevated UACR.
Participants with elevated UACR were more likely to be
older and have higher rates of cardiovascular risk factors,
including hypertension, DM, obesity (greater body mass
index), and history of CAD.
On echocardiographic analysis, higher levels of UACR were
associated with increased LV mass and increased prevalence
of LVH across quartiles. Diastolic function was worse (including lower E/A ratio and increased isovolumic relaxation time)
with increasing levels of UACR. Arterial stiffness increased
Q2
Q3
Q4
n=473
n=474
n=472
n=475
<2.4
2.44.1
4.18.8
>8.8
<2.1
2.13.3
3.37.3
>7.3
50.713.1
5313.5
P Value
Clinical characteristic
Age, y
50.413.3
Females, n (%)
279 (59)
281 (59)
279 (59)
281 (59)
0.06
Black, n (%)
169 (36)
192 (41)
219 (46)
285 (60)
<0.001
12017
12117
12820
13424
<0.001
7010
709.6
7310.9
7411.3
<0.001
24 (5)
17 (4)
29 (6)
50 (11)
<0.001
212 (45)
207 (44)
300 (64)
351 (74)
<0.001
40 (9)
50 (11)
70 (15)
147 (31)
<0.001
204 (43)
178 (38)
205 (44)
220 (47)
0.15
BMI, kg/m2
29.86.6
30.46.6
30.46.8
32.17.5
<0.001
Hypertension, n (%)
Diabetes mellitus, n (%)
4813.8
0.001
GFR, ml/min/1.73m2
8018
8718
8819
8624
0.04
9754
11961
12059
10653
0.13
2816
3518
3520
3220
0.08
190 (40)
186 (39)
251 (53)
307 (65)
<0.001
Beta blocker
62 (13)
48 (10)
61 (13)
67 (14)
0.80
69 (15)
67 (14)
110 (23)
164 (35)
<0.001
Nondihydropyridine
31 (7)
28 (6)
48 (10)
66 (14)
<0.001
Dihydropyridine
38 (8)
40 (8)
62 (13)
98 (21)
<0.001
10 (2)
8 (2)
17 (4)
12 (3)
0.78
71 (15)
83 (18)
92 (20)
129 (27)
<0.001
Thiazide diuretic
49 (10)
48 (10)
75 (16)
69 (15)
0.08
Sympatholytic
30 (6)
16 (3)
45 (10)
52 (11)
0.08
Statin
36 (8)
29 (6)
32 (7)
43 (9)
0.70
Echocardiographic characteristic
LV end systolic volume, ml
47.114.4
46.915.6
47.314.8
48.515.5
0.38
125.125.2
125.828.2
126.226.7
129.127.9
0.17
Ejection fraction, %
62.85.7
63.36.1
63.15.8
635.7
0.68
79.215.7
80.317.9
84.218.3
89.726.1
<0.001
50 (11)
58 (12)
81 (17)
121 (25)
<0.001
1.240.21
1.260.22
1.310.23
1.380.33
<0.001
3.40.5
3.50.5
3.50.5
0.01
3.40.5
Stroke volume, ml
7514.4
2.50.5
2.60.6
0.700.20
76.917.5
7715.4
78.416.1
0.09
2.70.6
2.70.6
<0.001
0.700.21
0.730.24
0.750.24
<0.001
63.716.6
68.718.5
67.820.8
66.719.8
60.318
62.518.9
67.719.4
71.621
<0.001
0.22
1.30.5
1.30.5
1.20.5
1.10.5
<0.001
201.254.7
201.254.7
199.355.2
213.566.2
0.02
77.716.1
78.016.9
81.819
81.918.7
0.003
Continuous data presented as meanSD. BMI indicates body mass index; GFR, glomerular filtration rate; LV, left ventricular; and UACR, urinary albumin to creatinine ratio
46CirculationJanuary 7, 2014
Figure 1. Cardiac indices by urine albumin-to-creatinine ratio (UACR) quartile. Estimated means and 95% confidence intervals for global
longitudinal strain (GLS; A), global circumferential strain (GCS; B), global radial strain (GRS; C), early diastolic (e) tissue velocity (D),
and E/e ratio (E) by UACR quartile, adjusted only for relatedness among participants. P for trend indicates significance of association
between log-transformed UACR and cardiac indices in linear mixed effects models (which accounts for relatedness among participants).
Tissue velocities by speckle tracking are lower than values observed using tissue Doppler. Thus e tissue velocity is lower and E/e is
higher than observed with tissue Doppler imaging.
Table3 demonstrates the association between UACR and cardiac indices in participants with UACR <30 mg/g (n=1722). On
multivariable analysis, UACR remained associated with both
longitudinal and circumferential strain, indicating that even in
Discussion
Figure 2. Cardiac indices by urine albumin-to-creatinine ratio (UACR) quartile after multivariable adjustment. *P value <0.05 when
compared with the referent quartile (Quartile 1). P value <0.02 for continuous trend. P value <0.001 for continuous trend. The
estimated means (with upper 95% confidence limits) for global longitudinal strain (GLS; A), global circumferential strain (GCS; B), global
radial strain (GRS; C), early diastolic (e) tissue velocity (D), and E/e ratio (E) are shown by UACR quartile for all subjects and 3 subgroups
after adjustment for speckle-tracking analyst, study site, image quality, age, sex, body mass index, estimated glomerular filtration rate,
diabetes mellitus, coronary artery disease, systolic blood pressure, use of antihypertensive medication, history of smoking, left ventricular
mass index, and ejection fraction. Tissue velocities by speckle tracking are lower than values observed using tissue Doppler. Thus e
tissue velocity is lower and E/e is higher than observed with tissue Doppler. DM indicates diabetes mellitus; HTN, hypertension; and LVH,
left ventricular hypertrophy.
Model 2
-Coefficient
(95% CI)
Model 4
-Coefficient
(95% CI)
GLS (all
subjects)
0.16
(0.24, 0.08)
<0.001
0.17
(0.25, 0.09)
<0.001
0.16
(0.23, 0.08)
<0.001
0.13
(0.21, 0.05)
0.001
0.16
(0.24, 0.08)
<0.001
0.19
(0.28, 0.11)
<0.001
0.21
(0.29, 0.12)
<0.001
0.19
(0.28, 0.11)
<0.001
0.18
(0.26, 0.09)
<0.001
0.2
(0.28, 0.11)
<0.001
0.17
(0.26, 0.08)
<0.001
0.18
(0.27, 0.09)
<0.001
0.17
(0.26, 0.08)
<0.001
0.13
(0.22, 0.04)
0.004
0.17
(0.26, 0.08)
<0.001
GLS (UACR
<30mg/g)
0.21
(0.32, 0.10)
<0.001
0.23
(0.35, 0.12)
<0.001
0.21
(0.32, 0.09)
<0.001
0.17
(0.28, 0.05)
0.004
0.22
(0.34, 0.11)
<0.001
P Value
P Value
-Coefficient
(95% CI)
Model 5
Cardiac
Parameter
P Value
-Coefficient
(95% CI)
Model 3
P Value
-Coefficient
(95% CI)
P Value
E/e ratio
(all subjects)
0.78
(0.27, 1.29)
0.003
0.81
(0.30, 1.32)
0.002
0.77
(0.26, 1.27)
0.003
0.56
(0.17, 0.95)
0.005
0.61
(0.08, 1.15)
0.025
E/e ratio
(no DM)
0.70
(0.17, 1.22)
0.009
0.72
(0.19, 1.25)
0.007
0.69
(0.17, 1.22)
0.009
0.46
(0.06, 0.85)
0.02
0.59
(0.03, 1.14)
0.04
-coefficient shown represents change in cardiac index per doubling of UACR. CI indicates confidence interval; DM, diabetes mellitus; GLS, global longitudinal strain;
LVH, left ventricular hypertrophy; and UACR, urinary albumin-to-creatinine ratio.
Model 1: Adjusted for speckle-tracking analyst, study site, image quality, age, sex, body mass index, estimated glomerular filtration rate, diabetes mellitus, coronary
artery disease, systolic blood pressure, use of any antihypertensive medication, history of smoking, left ventricular mass index, and ejection fraction.
Model 2: Model 1 except adjusted for ethnicity instead of study site.
Model 3: Model 1 except adjusted for angiotensin converting enzyme inhibitor/angiotensin II receptor blocker and nondihydropyridine calcium channel blocker use
instead of any antihypertensive.
Model 4: Model 1 + additional adjustment for e velocity as a marker of diastolic dysfunction.
Model 5: Model 1 + additional adjustment for pulse pressure/stroke volume as a marker of arterial stiffness.
P Value
Global longitudinal
strain, %
<0.001
Global circumferential
strain, %
0.005
0.12
e velocity, cm/s
0.09
0.18
E/e ratio
48CirculationJanuary 7, 2014
and longitudinal strain was present in the entire cohort, those
without DM, and those without LVH. In the subgroup of normotensives, a similar association was present but did not meet
statistical significance, a finding that may be explained by the
sample size in Quartile 4 (n=124 normotensives who had UACR
levels that placed them in the highest UACR quartile [Quartile
4]). Importantly, only a small proportion of participants in our
study had clinically defined micro- or macroalbuminuria (7%
with UACR=30300 mg/g and 3% with UACR >300 mg/g,
respectively). An analysis of subjects with normal UACR (< 30
mg/g) did not alter the relationship between UACR and GLS.
Taken together, these results support a continuous relationship
between albuminuria and subclinical myocardial dysfunction
and suggest that there is a link between endothelial dysfunction
and abnormal myocardial mechanics.
Albuminuria is thought to be the result of endothelial damage in the glomerulus.25,26 In DM and hypertension, endothelial
dysfunction is a global phenomenon. The cause of albuminuria
in persons without DM or hypertension is less clear, though
increased UACR has been linked to progression to hypertension in these individuals.27 Proteinuria occurs in dogs with
renal venous congestion, and reduced renal blood flow has
been associated with albuminuria in humans.2830 Thus, it has
been suggested that in HF, adverse hemodynamics may play
a role in albuminuria in the absence of hypertension or DM.6
Although HyperGEN participants did not have clinically evident HF, it is possible that subtle hemodynamic abnormalities
play a role in the relationship observed in our study. Renal
blood flow was not measured in HyperGEN, though models
controlling for cardiac index (estimated on echocardiography)
did not alter our results (data not shown). In addition, adjusting for GFR in our multivariable models did not attenuate the
association between UACR and longitudinal strain.
An unobserved cause of both albuminuria and myocardial
dysfunction, such as inflammation, may also account for the
results.31 However, inflammatory markers such as C-reactive
protein or interleukin-6 were not measured in HyperGEN.
Alternatively, endothelial dysfunction leading simultaneously
to albuminuria and subclinical CAD could explain the association.32,33 However, assessment of subclinical CAD (ie, coronary artery calcium) was not performed in HyperGEN.
Although the mechanism is unclear, our data suggest that
albuminuria, even at low levels, is associated with adverse cardiac mechanics after adjustment for several risk factors and
conventional echocardiographic parameters. These findings
highlight a group of asymptomatic individuals who may be at
increased risk for overt myocardial dysfunction and progression to HF.
Conclusions
Albuminuria, even at low levels, is associated with worse cardiac mechanics and higher E/e ratio. The association between
albuminuria and worse mechanics and higher E/e ratio is
present even in individuals without DM or LVH. These findings suggest a pathophysiological link between endothelial
dysfunction and early, subclinical myocardial dysfunction.
Future studies of therapies aimed at improving endothelial
dysfunction may be helpful in determining whether decreasing UACR results in preservation of myocardial function.
Sources of Funding
The HyperGEN cardiac mechanics ancillary study was funded by
the National Institutes of Health (R01 HL 107577 to Dr Shah). The
HyperGEN parent study was funded by cooperative agreements
(U10) with the National Heart, Lung, and Blood Institute: HL54471,
HL54472, HL54473, HL54495, HL54496, HL54497, HL54509,
HL54515.
Disclosures
None.
References
1. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van
Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE;
Prevention of Renal and Vascular End Stage Disease (PREVEND)
Study Group. Urinary albumin excretion predicts cardiovascular
and noncardiovascular mortality in general population. Circulation.
2002;106:17771782.
2. Arnlv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ,
DAgostino RB, Vasan RS. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005;112:969975.
3. Deckert T, Yokoyama H, Mathiesen E, Rnn B, Jensen T, Feldt-Rasmussen
B, Borch-Johnsen K, Jensen JS. Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients
with insulin dependent diabetes. BMJ. 1996;312:871874.
4. Miettinen H, Haffner SM, Lehto S, Rnnemaa T, Pyrl K, Laakso M.
Proteinuria predicts stroke and other atherosclerotic vascular disease
events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke.
1996;27:20332039.
5. Solomon SD, Lin J, Solomon CG, Jablonski KA, Rice MM, Steffes
M, Domanski M, Hsia J, Gersh BJ, Arnold JM, Rouleau J, Braunwald
E, Pfeffer MA; Prevention of Events With ACE Inhibition (PEACE)
Investigators. Influence of albuminuria on cardiovascular risk in patients
with stable coronary artery disease. Circulation. 2007;116:26872693.
6. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson
B, Michelson EL, Granger CB, Swedberg K, Pfeffer MA, Yusuf S,
McMurray JJ; CHARM Investigators and Committees. Albuminuria
in chronic heart failure: prevalence and prognostic importance. Lancet.
2009;374:543550.
7. Jackson CE, MacDonald MR, Petrie MC, Solomon SD, Pitt B, Latini
R, Maggioni AP, Smith BA, Prescott MF, Lewsey J, McMurray JJ;
ALiskiren Observation of heart Failure Treatment (ALOFT) investigators.
Associations of albuminuria in patients with chronic heart failure: findings
in the ALiskiren Observation of heart Failure Treatment study. Eur J Heart
Fail. 2011;13:746754.
8. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B,
Hall JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S; HOPE
Study Investigators. Albuminuria and risk of cardiovascular events,
death, and heart failure in diabetic and nondiabetic individuals. JAMA.
2001;286:421426.
9. Djouss L, Kochar J, Hunt SC, North KE, Gu CC, Tang W, Arnett DK,
Devereux RB. Relation of albuminuria to left ventricular mass (from the
HyperGEN Study). Am J Cardiol. 2008;101:212216.
10. Wachtell K, Olsen MH, Dahlf B, Devereux RB, Kjeldsen SE, Nieminen
MS, Okin PM, Papademetriou V, Mogensen CE, Borch-Johnsen K,
Ibsen H. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens.
2002;20:405412.
11. Bilge AK, Atilgan D, Onur I, Pamukcu B, Ozcan M, Adalet K.
Relationship between left ventricular hypertrophy, hypertensive
retinopathy, microalbuminuria and echocardiographic modalities in
newly diagnosed hypertensive patients. Int J Cardiovasc Imaging.
2010;26:405412.
12. Shim CY, Park S, Choi EY, Kang SM, Cha BS, Ha JW, Rim SJ, Lee HC,
Chung N. Is albuminuria an indicator of myocardial dysfunction in diabetic patients without overt heart disease? A study with Doppler strain and
strain rate imaging. Metab Clin Exp. 2008;57:448452.
13. Williams RR, Rao DC, Ellison RC, Arnett DK, Heiss G, Oberman A,
Eckfeldt JH, Leppert MF, Province MA, Mockrin SC, Hunt SC. NHLBI
family blood pressure program: methodology and recruitment in the
HyperGEN network. Hypertension genetic epidemiology network. Ann
Epidemiol. 2000;10:389400.
14. Freedman BI, Beck SR, Rich SS, Heiss G, Lewis CE, Turner S, Province
MA, Schwander KL, Arnett DK, Mellen BG; HyperGEN Investigators. A
genome-wide scan for urinary albumin excretion in hypertensive families.
Hypertension. 2003;42:291296.
15. Devereux RB, Roman MJ, de Simone G, OGrady MJ, Paranicas M, Yeh
JL, Fabsitz RR, Howard BV. Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong
Heart Study. Circulation. 1997;96:14161423.
16. Palmieri V, Dahlf B, DeQuattro V, Sharpe N, Bella JN, de Simone G,
Paranicas M, Fishman D, Devereux RB. Reliability of echocardiographic
assessment of left ventricular structure and function: the PRESERVE
study. Prospective Randomized Study Evaluating Regression of
Ventricular Enlargement. J Am Coll Cardiol. 1999;34:16251632.
50CirculationJanuary 7, 2014
Doppler imaging in the estimation of left ventricular filling pressures:
A comparative simultaneous Doppler-catheterization study. Circulation.
2000;102:17881794.
36. Sharp AS, Tapp RJ, Thom SA, Francis DP, Hughes AD, Stanton AV,
Zambanini A, OBrien E, Chaturvedi N, Lyons S, Byrd S, Poulter NR,
Sever PS, Mayet J; ASCOT Investigators. Tissue Doppler E/E ratio is a
Clinical Perspective
Albuminuria, as measured by the urine albumin to creatinine ratio (UACR), predicts cardiovascular events in hypertension,
diabetes mellitus, and heart failure. The reasons underlying the association between elevated UACR and worse cardiovascular outcomes are unclear but may be attributable to the relationship between endothelial dysfunction and intrinsic myocardial
dysfunction. We therefore sought to study the relationship between UACR and cardiac mechanics (measured by speckletracking echocardiography) in the Hypertension Genetic Epidemiology Network (HyperGEN) Study, a population- and
family-based study of hypertensive and normotensive individuals. In a sample of 1894 HyperGEN participants, all of whom
had ejection fraction >50% and normal wall motion, we demonstrated a continuous, linear relationship between UACR and
cardiac mechanics, especially global longitudinal strain. The relationship between increased UACR and worse longitudinal
strain persisted after adjustment for multiple confounders and in subgroup analyses. These associations were even present
in individuals with UACR levels in the normal range (< 30 mg/g). Observing this relationship in the diverse, ambulatory
HyperGEN cohort after controlling for comorbiditiesespecially diabetes mellitus and hypertensionsuggests that UACR,
as a marker for endothelial dysfunction, may share a pathophysiologic link with intrinsic myocardial dysfunction even in
very early, asymptomatic stages. These findings highlight the possibility that early treatment of endothelial dysfunction may
be a way to prevent the onset of myocardial dysfunction in at-risk patients.
The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circ.ahajournals.org/content/129/1/42
Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.
Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints
Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/
SUPPLEMENTAL MATERIAL
Supplementary Table S1. Reproducibility Data for Measurements of Cardiac Mechanics (N=95)*
Interobserver Reproducibility
Parameter
Global longitudinal strain, %
Global circumferential strain, %
Global radial strain, %
e velocity, cm/s
MeanSD
15.32.7
21.65.0
27.29.7
2.71.1
ICC
(95% CI)
0.77 (0.69, 0.85)
0.76 (0.67, 0.85)
0.92 (0.89, 0.95)
0.76 (0.67, 0.84)
Mean bias
(95% CI)
0.71 (0.34-1.08)
1.22 (0.52, 1.93)
-0.39 (-1.17, 0.38)
-0.11 (-0.28, 0.06)
Intraobserver Reproducibility
CV
9.9%
13.6%
11.1%
26.9%
ICC
(95% CI)
0.90 (0.87, 0.94)
0.88 (0.83, 0.93)
0.92 (0.88, 0.95)
0.81 (0.75, 0.88)
Mean bias
(95% CI)
-0.17 (-0.46, 0.11)
-0.52 (-0.06, 1.09)
0.66 (0.10, 1.42)
-0.09 (-0.24, 0.06)
CV
7.2%
9.6%
11.3%
22.3%
-coefficient per
doubling of UACR
-0.45
-0.36
-0.36
-0.28
-0.28
-0.29
-0.29
-0.27
-0.27
-0.27
-0.22
-0.22
-0.22
-0.22
-0.23
95% CI
-0.56, -0.33
-0.46, -0.25
-0.46, -0.25
-0.38, -0.18
-0.38, -0.18
-0.39, -0.19
-0.39, -0.18
-0.37, -0.17
-0.37, -0.16
-0.37, -0.16
-0.33, -0.11
-0.33, -0.11
-0.33, -0.11
-0.33, -0.11
-0.34, -0.12
-coefficient per
doubling of UACR
-0.45
-0.45
-0.45
-0.45
-0.45
-0.44
-0.43
-0.43
-0.43
-0.41
-0.40
-0.37
-0.36
-0.36
95% CI
-0.56, -0.33
-0.57, -0.34
-0.56, -0.33
-0.56, -0.34
-0.57, -0.34
-0.56, -0.32
-0.55, -0.31
-0.54, -0.31
-0.55, -0.32
-0.53, -0.30
-0.52, -0.28
-0.49, -0.25
-0.46, -0.25
-0.47, -0.25
The -coefficients shown above are for the association between UACR and global longitudinal
strain when each individual covariate is added to the base model (which accounts for family
relatedness). Thus, each beta-coefficient above is for a model that contains only the covariate,
family relatedness, and UACR (in contrast to the stepwise addition of covariates shown above in
Supplementary Table S2). UACR = urinary albumin-to-creatinine ratio. CI=confidence interval.